You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑞普生物(300119.SZ)擬向艾棣維欣增資1200萬元 佔股3.1579%
格隆匯 03-09 20:51

格隆匯3月9日丨瑞普生物(300119.SZ)公佈,公司於2020年3月9日與鵬鷂環保股份有限公司(“鵬鷂環保”)、北京艾棣維欣生物技術有限公司(“艾棣維欣”或“標的公司”)、俞慶齡簽署《北京艾棣維欣生物技術有限公司增資協議》(“增資協議”),公司以自有資金1200萬元對北京艾棣維欣生物技術有限公司進行增資,其中51.4286萬元計入標的公司註冊資本,投資完成後,瑞普生物持有標的公司3.1579%的股權。

標的公司主營業務為新型疫苗的研發。在研的核心品種分別是RSV預防性疫苗、乙肝治療性疫苗、I型糖尿病治療性疫苗、冠狀病毒疫苗。標的公司擬研發的疫苗一般需經歷概念驗證、臨牀前、臨牀I期、臨牀II期、臨牀III期、申報上市等階段。

各方同意,投資方對標的公司的全部出資主要用於目標公司主營業務(應優先保證新型冠狀病毒2019-nCoV疫苗開發)以及有助於提升標的公司發展的其他事項,包含但不限於以下內容:購買經營設備、招聘新員工、研究開發新服務產品、補充流動資金,或經公司董事會批准的其它用途,不得用於股票投資、回購老股東股權、委託貸款和期貨交易。

標的公司與美國Inovio Pharmaceuticals,Inc.達成合作,利用國際水平的DNA疫苗技術平台合作進行項目開發。通過此次投資,公司與標的公司建立了長期穩定的戰略合作關係,且標的公司在已有多個財務投資方的基礎上,與公司共同達成戰略合作,結合公司已有經過靜態驗收並擬用於DNA疫苗生產的專用GMP車間以及新產品註冊和生產工藝轉化優勢,雙方可實現強強聯合與優勢互補,以期加強公司DNA疫苗技術佈局。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account